Dr. Antoni Ribas

Dr. Antoni Ribas, MD, PhD, is a globally renowned medical oncologist and leading authority in cancer immunotherapy, celebrated for his transformative research in immune checkpoint blockade and translational melanoma therapy. He serves as Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA, Director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program, and Director of the Parker Institute for Cancer Immunotherapy Center at UCLA. Dr. Ribas earned his medical degree and PhD from the University of Barcelona, completed his residency in Internal Medicine at Vall d’Hebron University Hospital, and his fellowship in Hematology/Oncology at UCLA. He is board-certified in Internal Medicine and Medical Oncology and is internationally recognized for his leadership in advancing cancer immunotherapy from bench to bedside.

A driving force behind the development of PD-1 immune checkpoint inhibitors, Dr. Ribas has led pivotal clinical trials that established anti-PD-1 therapies as standard of care for advanced melanoma. His translational research has unveiled critical mechanisms of tumor immune evasion, resistance to immunotherapy, and strategies to enhance T-cell mediated tumor eradication. Dr. Ribas’s laboratory continues to innovate approaches in combination immunotherapy, oncolytic viruses, and adoptive T-cell strategies to broaden the efficacy of immunotherapy across solid tumors. He has authored over 350 peer-reviewed publications and is among the most cited researchers in oncology and immunology.

Beyond his research impact, Dr. Ribas is a dedicated mentor and global thought leader in immuno-oncology. He has trained numerous physician-scientists who are now leading immunotherapy programs worldwide and has played a key role in shaping international immunotherapy strategies through leadership positions in major cancer research organizations. His contributions continue to drive the evolution of cancer immunotherapy, improving outcomes for patients with advanced malignancies globally.